Skip to main content

Mycobacterium Infections, Nontuberculous

1
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
LAI plus multi-drug regimenPhase 2
Insmed
InsmedBRIDGEWATER, NJ
5 programs
LAI plus multi-drug regimenPHASE_21 trial
Liposomal amikacin for inhalationPHASE_2
ALISPHASE_31 trial
ALISPHASE_31 trial
LAIPHASE_31 trial
Active Trials
NCT03038178Completed30Est. Dec 2019
NCT04677569Completed425Est. Jan 2026
NCT04677543Completed99Est. May 2023
+1 more trials
Paratek Pharmaceuticals
1 program
Omadacycline Oral TabletPHASE_21 trial
Active Trials
NCT04922554Completed66Est. Jul 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
InsmedALIS
InsmedALIS
InsmedLAI
Paratek PharmaceuticalsOmadacycline Oral Tablet
InsmedLAI plus multi-drug regimen

Clinical Trials (5)

Total enrollment: 956 patients across 5 trials

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Start: Apr 2021Est. completion: Jan 2026425 patients
Phase 3Completed

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Start: Dec 2020Est. completion: May 202399 patients
Phase 3Completed

Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

Start: May 2015Est. completion: Apr 2019336 patients
Phase 3Completed
NCT04922554Paratek PharmaceuticalsOmadacycline Oral Tablet

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Start: Oct 2021Est. completion: Jul 202466 patients
Phase 2Completed
NCT03038178InsmedLAI plus multi-drug regimen

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

Start: Oct 2016Est. completion: Dec 201930 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.